ClinicalTrials.gg
Active, not recruitingNCT02523443Updated Sep 15, 2026

Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection

A Phase 3 interventional study of IV PCA and PCEA in Liver Cancer and Pain Management, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Liver Neoplasms by Memorial Sloan Kettering Cancer Center — none open to participants now, 3 under way, 1 of them phase 3. Liver Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
2nd of 14
231 · median 69
Started
2015
the only one that year
Phase 3
3 of 22
none open now
Registered
19th of 22
by date

Among the 22 studies in Liver Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 19th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

None of the 22 studies in Liver Neoplasms by Memorial Sloan Kettering Cancer Center is open now. The open studies under Liver Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Liver Neoplasms by Memorial Sloan Kettering Cancer Center as a file.
02

Study summary

The purpose of this study is to learn whether patient-controlled epidural analgesia (PCEA) is a better method for managing pain after liver resection compared to patient-controlled analgesia (IV PCA). Currently, the standard pain control method for liver resection patients is IV PCA. There is not enough data on how epidural (PCEA) relieves pain and movement on a day to day basis after liver resection.

03

Conditions studied

  • Liver Cancer
  • Pain Management

Browse trials for

Keywords

  • Epidural Analgesia
  • Intravenous Patient Controlled
  • 15-148
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age 18 years or older) who are able to provide .
  • Patients undergoing open elective liver resection for primary liver pathology (benign or malignant) or secondary liver disease, including patients undergoing concomitant surgical procedures (such as colorectal resection or debulking procedures), with no to the insertion of an epidural catheter (localized infection, septicemia, or pre-operative coagulopathy).

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of documented anaphylaxis or to any of the study medications or standardized intra-operative medications. These include dilaudid, fentanyl, and bupivacaine.
  • Patients with pain at rest or with movement measured by NRS >2.
  • Patients receiving high dose opioids on a chronic basis (greater than or equivalent to 60mg of morphine per day).
  • Patients with severe (COPD) defined as an \<50%.
  • Patients with significant cognitive impairment or documented psychologic impairment.
  • Contraindication to epidural catheter placement including bleeding diathesis (essential thrombocythemia, idiopathic thrombocytopenic purpura, von Willebrand disease, and hemophilia A or B), neurological dysfunction (multiple sclerosis, subacute myelo-opticoneuropathy or preexisting lower limb neurological deficit), prior extensive spinal surgery or major spinal deformity, pre-operative use of anti-coagulant with planned use of therapeutic dose of anti-coagulant in post-operatively, documented pre-operative coagulopathy ( greater than 1.3 not on Coumadin or PTT greater than 42), less than 100,000/μL, or evidence of infection at potential epidural site.
  • Cirrhotic patients. When incidentally discovered intra-operatively, patients will be excluded from the study and replaced, but will be followed for primary and secondary endpoints.
  • Patients with poor performance status preoperatively such that they are unable to walk up two flights of stairs.
  • Patients taking any opioid agonist/antagonist medication (i.e. Buprenorphine)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
231 participants (estimated)

Study arms

  • Active comparator
    IV PCA after surgery

    general anesthesia with post-operative IV PCA with a standard demand pump

    Other: IV PCA

  • Experimental
    PCEA during and after surgery

    general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump

    Other: PCEA

Interventions

  • OtherIV PCA

    Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.

  • OtherPCEA

    Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.

06

What researchers measure

Primary outcomes

  1. ability to detect a 2-point NRS scale difference

    The primary endpoint assesses differences in pain control between PCEA and IV PCA after a "get up and go" test performed on POD2 during pain rounds, evaluated using a NRS pain score.

    Time frame: 1 year

07

Study locations

3 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2015 (actual). Primary completion is estimated for Aug 2027, 144 months after the start.

Of 30 phase 3 interventional studies under Liver Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 97. This study's planned 144 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2015
First posted
Aug 14, 2015
StartActual
Aug 2015
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02523443
Responsible party
Sponsor
First posted
Aug 14, 2015
Start date
Aug 2015
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Vittoria Arslan-Carlon, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion